ICU sedation, delirium & recovery
Functional Status After Delirium in the ICU: A 1-Year Follow-Up of the Agents Intervening Against Delirium in the ICU (AID-ICU) Trial
Authors' conclusion
Among adult ICU patients with delirium, treatment with haloperidol vs. placebo did not result in statistically significant differences in functional status at 1-year follow-up.
Study context
- Population
- Adult ICU patients with delirium enrolled in the AID-ICU trial at 3 Danish sites144 followed up
- Participants
- 632 patients
- Comparison
- Haloperidol vs placebo
- Haloperidoln = 75
- Placebon = 69reference
- Primary endpoint
- Functional status (Lawton-Brody Instrumental Activities of Daily Living (IADL), Barthel-20 Activities of Daily Living (ADL), Clinical Frailty Scale, grip strength); nonsurvivors assigned worst values
- Follow-up
- 1 year
Methodological detailspreplanned 1-year follow-up, placebo-controlled, blinded, Follow-up by telephone in 28.5% of responders (41/144), Relatives answered on behalf of participants in 4.2% (6/144)
- Preplanned 1-year follow-up
- Placebo-controlled
- Blinded
- Follow-up by telephone in 28.5% of responders (41/144)
- Relatives answered on behalf of participants in 4.2% (6/144)
Primary result
As reported in the abstract
Each group vs placeboEstimate (95% CI)P value
Haloperidol
adjusted mean difference (IADL) 0.1(−0.5 to 0.7)
P = 0.687Haloperidol
adjusted mean difference (ADL) 0.2(−1.3 to 1.7)
P = 0.773Haloperidol
adjusted mean difference (CFS) 0.0(−0.4 to 0.5)
P = 0.862Haloperidol
adjusted mean difference (grip strength) −2.9(−7.1 to 1.2)
P = 0.175Original publication
Functional Status After Delirium in the ICU: A 1-Year Follow-Up of the Agents Intervening Against Delirium in the ICU (AID-ICU) Trial. Crit Care Med. Published 19 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →